Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Check out some of our latest original content that was created and distributed as part of our ongoing collaborations with IR firms and other companies.

MissionIRNewsBreaks – Platinum Group Metals Ltd. (NYSE American: PLG) (TSX: PTM) Closes $1 Million Private Placement with HCI

Posted on May 30, 2025 by MissionIR

Platinum Group Metals (NYSE American: PLG) (TSX: PTM) has closed a US$1.008 million non-brokered private placement with major shareholder Hosken Consolidated Investments Limited (“HCI”) via its subsidiary Deepkloof Limited. The transaction, completed May 29, 2025, involved the issuance of 800,000 common shares at US$1.26 per share, restoring HCI’s ownership to 26%. Proceeds will support pre-construction and engineering work at the Waterberg Project in South Africa, along with general corporate purposes. As HCI is a related party, the deal qualifies for exemptions under MI 61-101 and was negotiated on an expedited basis.

To view the full press release, visit https://ibn.fm/KvEH7

About Platinum Group Metals Ltd.

Platinum Group Metals is the operator of the Waterberg Project, a bulk underground palladium and platinum deposit located in South Africa. The Waterberg Project was discovered by Platinum Group and is being jointly developed with Implats, Mnombo and HJM. For more information about the company, visit www.PlatinumGroupMetals.net.

NOTE TO INVESTORS: The latest news and updates relating to PLG are available in the company’s newsroom at https://ibn.fm/PLG

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
Editor@MissionIR.com

MissionIR is powered by IBN

Posted in Platinum Group Metals Ltd. PLG | Leave a comment

D-Wave Quantum Inc. (NYSE: QBTS) CEO Highlights Revenue Increase, Commercial and Technical Momentum, in Fox Business Interview

Posted on May 29, 2025 by MissionIR
  • D-Wave reported Q1 2025 revenue of $15 million, up 509% year over year.
  • The revenue jump was driven by the sale of an Advantage(TM) quantum system to the Jülich Supercomputing Centre in Germany.
  • CEO Dr. Alan Baratz says D-Wave’s recent quantum supremacy demonstration influenced the sale, while also catching the attention of the supercomputer community and national labs around the world.
  • Dr. Baratz reiterated that annealing quantum computing is uniquely suited for real-world optimization tasks.

D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software, and services, is seeing momentum build on both the technical and commercial fronts, according to CEO Dr. Alan Baratz, who appeared on Fox Business’ The Claman Countdown to discuss the company’s progress (https://ibn.fm/fVsGS).

Baratz emphasized a significant milestone recently achieved by the company: the sale of a D-Wave(TM) Advantage quantum computing system to Germany’s Jülich Supercomputing Centre (“JSC”), a deal that contributed to a sharp increase in Q1 revenue. D-Wave reported quarterly revenue of $15 million, a 509% increase compared to $2.5 million in the same quarter last year. The gain was primarily attributed to the Advantage system sale to JSC.

The installation at JSC is notable not only for the revenue it generated but also for its technical implications. The Advantage system is anticipated to be integrated with JUPITER, Europe’s first exascale supercomputer. JUPITER is expected to perform over one quintillion calculations per second, and its coupling with a quantum annealing machine could represent a unique configuration aimed at exploring hybrid quantum-classical computing models. The integration of an annealing quantum computer with an exascale system may open up new research opportunities in materials science, AI optimization, financial modeling, and other areas that require solving complex computational problems.

The sale came on the heels of D-Wave’s recent demonstration of quantum supremacy. In that demonstration, the company’s Advantage2(TM) annealing quantum computing system outperformed a classical supercomputer in solving a magnetic materials simulation problem. During the Fox Business interview, Baratz said the results “caught the attention of the supercomputer community and national labs around the world with a realization that these systems could be used to do some very interesting deep research into new areas” (https://ibn.fm/m0b8e).

Annealing quantum computing systems are uniquely suited for real-world optimization problems faced by businesses today in sectors like logistics, finance, and manufacturing. The D-Wave CEO emphasized that his company’s technology is used in real-world applications for multiple clients now, including Ford Otosan, which deployed a hybrid-quantum application to reduce vehicle production scheduling time from 30 minutes to under five minutes, and Japan Tobacco’s pharma unit, which is using D-Wave’s quantum computer in a drug discovery pilot project, yielding improved molecular structures compared to classical-only approaches.

About D-Wave Quantum Inc.

D-Wave is a leader in the development and delivery of quantum computing systems, software, and services. We are the world’s first commercial supplier of quantum computers, and the only company building both annealing and gate-model quantum computers. Our mission is to help customers realize the value of quantum, today. Our quantum computers, the world’s largest, are available on-premises or via the cloud, supported by 99.9% availability and uptime. More than 100 organizations trust D-Wave with their toughest computational challenges. With over 200 million problems submitted to our quantum systems to date, our customers apply our technology to address use cases spanning optimization, artificial intelligence, research and more. Learn more about realizing the value of quantum computing today and how we’re shaping the quantum-driven industrial and societal advancements of tomorrow: www.dwavequantum.com

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of our most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of our Quarterly Reports on Form 10-Q and in our other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com

MissionIR is powered by IBN

Posted in D-Wave Quantum Inc. QBTS | Leave a comment

Newton Golf Company Inc. (NASDAQ: NWTG) Releases Financial Report, Business Highlights for Q1 2025

Posted on May 28, 2025 by MissionIR
  • Newton Golf reports three-figure revenue growth in first quarter of 2025.
  • Newton Motion shaft adoption has surpassed 30 professionals.
  • Company’s revenue guidance for 2025 is forecast to range between $6.5 and $7 million.

With the launch of its newest shaft family, Newton Golf Company (NASDAQ: NWTG) is seeing triple-figure year-over-year revenue growth, according to the company’s latest financial numbers (https://ibn.fm/hAQWB). The company released its financial report for Q1 2025, noting that revenue had increased an impressive 246% during the first three months of the year.

“We are very pleased with our first-quarter results, especially given that it is typically the offseason for golf,” said Newton Golf CEO Greg Campbell. “When we launched the Newton Motion shaft, our goal was to engineer performance that speaks for itself. The fact that more than 30 professionals are now using Newton shafts across major tours — and that eight of those joined in Q1 — validates both the technology and our direction. We’re just getting started. Demand for our Fast Motion shaft has exceeded expectations, and we are ramping up production to keep pace.”

According to the company’s report, financial highlights for first quarter 2025 include revenue of $1.2 million, up from $350,000 in Q1 2024; an increase in gross profit of 348%, totaling $852,000, up from $190,000 in 2024; and gross margin reaching 70%, up from 54% a year ago. In addition, the report noted that net loss for the company decreased to $0.5 million, or $0.55 per share, compared to $1.2 million, or $24.85 per share in Q1 2024; the company reported cash and cash equivalents of $5.9 million as of March 31, 2025.

Perhaps most exciting for the company was the news that Newton Motion shaft adoption has surpassed 30 professionals, with eight new players joining across PGA TOUR Champions, LPGA, Korn Ferry and PGA TOUR events during the quarter. Other business highlights from the quarterly report included shaft sales growth of 314% year over year and the opportunity to showcase the company’s full product lineup at the 2025 PGA Show.

The quarterly report also noted the company’s growing international reach. Newton Golf signed distribution agreements with two of Japan’s largest golf retailers, and expanded product testing and engagement with club fitting leaders in Europe and North America.

In addition, the Q1 report noted the company’s revenue guidance for 2025, which is forecast to range between $6.5 and $7 million, representing continued strong growth from 2024. “We continue to execute with discipline and focus,” Campbell stated. “The 246% year-over-year revenue growth reflects strong demand, expanding distribution and improving unit economics.

“As we look ahead to the rest of 2025, our focus remains on expansion—new products, new markets, and continued tour validation,” Campbell continued. “We believe Newton’s trajectory is being driven by something deeper than hype. It’s being driven by results, by performance, and by trust on tour. And we’re building for the long-term.”

For more information, visit www.NewtonGolfCo.com.

NOTE TO INVESTORS: The latest news and updates relating to NWTG are available in the company’s newsroom at https://ibn.fm/NWTG

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com

MissionIR is powered by IBN

Posted in Small Cap News | Leave a comment

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Announces $10.3 Million Financing to Expand HOPE Clinic Network, Advances FDA Drug Approval

Posted on May 28, 2025 by MissionIR
  • Subsidiary HOPE Therapeutics signed a $7.8 million debt financing term sheet with Universal Capital.
  • Combined with a prior strategic investment, for which a financing term sheet has also been signed, the total financing investment, assuming both are closed, represents an expected $10.3 million for HOPE acquisition funding, supporting initial acquisitions of Dura Medical, Kadima, and NeuroSpa clinics.
  • The expanding HOPE clinic network will deliver neuroplastic therapies for depression and PTSD, including ketamine and TMS.
  • NRx continues regulatory progress for NRX-100 (IV ketamine) and NRX-101 (oral bipolar depression therapy).
  • The FDA waived NRx’s $4.3 million drug application fee, and patents could protect NRX-100 through 2045.

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, is advancing its twin strategy of expanding a nationwide mental health clinic network while progressing toward FDA approval of its NMDA-based therapies for suicidal depression and bipolar disorder.

The company’s wholly owned subsidiary, HOPE Therapeutics, Inc., a medical and technology-driven company, has signed a term sheet for $7.8 million in debt financing with Universal Capital, LLC (https://ibn.fm/tZzIa). The funds will support HOPE’s clinic acquisition strategy, starting with the previously announced acquisitions of Dura Medical, Kadima Neuropsychiatry Institute, and NeuroSpa TMS Holdings. Together with a separate strategic investment, for which a financing term sheet was signed earlier, HOPE expects to deploy $10.3 million in acquisition capital in the near term, once both agreements are closed.

The clinics will provide interventional psychiatric care focused on neuroplastic therapies like transcranial magnetic stimulation (“TMS”) and intravenous ketamine. These approaches are increasingly used to treat conditions including major depressive disorder, PTSD, and suicidality, offering alternatives to traditional pharmacological treatments.

The acquired clinics are expected to represent roughly $15 million in pro forma revenue for 2025. NRx has also entered talks with four additional clinical entities that could add another $20 million in revenue potential. Management’s stated goal is to scale to $100 million in forward-looking pro forma revenue by year-end.

HOPE Therapeutics has already begun serving veterans through VA contracts, with potential for significant expansion as more clinics come online. U.S. health officials, including the Secretary of Health and Human Services and the VA Secretary, have publicly emphasized the importance of psychedelic and neuroplastic treatments in addressing the nation’s suicide crisis.

HOPE’s expansion takes place as NRx moves closer to FDA approval for its proprietary ketamine formulation, NRX-100. The drug, a preservative-free IV ketamine therapy for suicidal depression, completed the stability and sterility testing needed for its New Drug Application (“NDA”). The NDA is on track to be filed in Q2 2025. The FDA has granted a waiver for the $4.3 million submission fee for NRX-100, and has previously assigned Fast Track Designation to the drug, according to the company’s Q1 financial results and corporate update (https://ibn.fm/cN2Nh).

In May, NRx filed a U.S. patent application for NRX-100, which may offer protection through 2045. The drug is designed to exclude benzethonium chloride, a preservative with known neurotoxicity, making it potentially the only FDA-approved IV ketamine without this additive. The company also announced development of HTX-100, a pH-neutral subcutaneous ketamine formulation, targeting broader outpatient use by eliminating the current formulation’s acidity and associated side effects.

The broader market opportunity for NRX-100 is substantial. Suicidal depression affects millions in the U.S. and is estimated to represent a $3 billion addressable market. 

In parallel, the company is advancing NRX-101, an oral therapy for bipolar depression with suicidality or akathisia. The drug has shown efficacy in late-stage trials and has already received Breakthrough Therapy Designation. A filing for accelerated approval is expected later in 2025, with a PDUFA date anticipated by year-end.

NRx presented these updates at the recent Wall Street Conference in Palm Beach, Florida, where the company was one of six featured presenters. Over 1,000 attendees representing more than $1 trillion in capital were present for the presentation given by CEO, Founder, and Chairman Jonathan Javitt, MD, MPH, underscoring investor interest in the company’s progress (https://ibn.fm/QJwZ0).

Commenting on the recent updates, Javitt underlined that the company’s 2024 momentum continued into 2025, as it has advanced regulatory filings for NRX-100 and NRX-101 and advanced commercial opportunity with potential new IP protection for NRX-100, now added to the company’s already robust NMDA IP portfolio. “We also took meaningful steps toward realizing our vision for HOPE Therapeutics as a national network of interventional psychiatry clinics—beginning with the announcements on the planned acquisition of Kadima, Dura Medical, and Neurospa TMS,” said Javitt. “These accomplishments reflect our team’s dedication to advancing mental health innovation and delivering life-saving treatments to patients in urgent need.”

For more information, visit the company’s website at www.NRxPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to NRXP are available in the company’s newsroom at https://ibn.fm/NRXP

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com

MissionIR is powered by IBN

Posted in NRx Pharmaceuticals Inc. NRXP | Leave a comment

MissionIRNewsBreaks – Newton Golf Company Inc. (NASDAQ: NWTG) Regains Nasdaq Compliance Following Strong Q1 Results

Posted on May 28, 2025 by MissionIR

Newton Golf Company (NASDAQ: NWTG) announced it has regained compliance with Nasdaq Listing Rule 5550(b)(1) after reporting $6.2 million in stockholders’ equity in its Q1 2025 10-Q filing. The Nasdaq confirmation closes a compliance matter originally raised in April. Executive Chairman Greg Campbell credited the resolution to the company’s financial strength and growing market traction. Newton Golf posted 246% year-over-year revenue growth in Q1 2025, with gross margins reaching 70%, driven by rising adoption of its Newton Motion shaft across retail channels and pro tours. Now used by over 40 professional players, the brand continues to expand globally and reinforce its innovation credentials within the performance golf segment.

To view the full press release, visit https://ibn.fm/lncyh

About Newton Golf

At Newton Golf, we harness the power of physics to revolutionize golf equipment design. Formerly known as Sacks Parente, our rebranding reflects our commitment to innovation inspired by Sir Isaac Newton, the father of physics. By applying Newtonian principles to every aspect of our design process, we create precision-engineered golf clubs that deliver unmatched stability, control, and performance. Our mission is to empower golfers with scientifically advanced equipment that maximizes consistency and accuracy, ensuring every swing is backed by the laws of physics.

NOTE TO INVESTORS: The latest news and updates relating to NWTG are available in the company’s newsroom at https://ibn.fm/NWTG

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
Editor@MissionIR.com

MissionIR is powered by IBN

Posted in Newton Golf Comp. NWTG | Leave a comment

Newton Golf Company Inc. (NASDAQ: NWTG) Unveils Fast Motion Shaft for Next-Level Play, Game-Changing Innovation

Posted on May 27, 2025 by MissionIR
  • Newton Golf’s new Fast Motion shaft exemplifies how a company can use innovation to sharpen its competitive edge.
  • The Fast Motion shaft incorporates several proprietary technologies that Newton Golf has developed over time.
  • This product launch is timely, as the golf equipment market continues to experience growth, driven by a surge in participation and a demand for premium gear.

Innovation has long been a driving force behind business growth, market disruption and brand longevity across nearly every sector of the global economy. In the world of sports equipment, few areas are as ripe for innovation as golf, where players are always seeking performance gains. Newton Golf Company (NASDAQ: NWTG) has seized this opportunity with the launch of its latest product: the Fast Motion shaft family (https://ibn.fm/9Z5jh). With this innovative new offering, the company aims to redefine performance standards and capitalize on the growing appetite for cutting-edge golf technology.

Companies that embrace forward-thinking ideas and invest in product development often find themselves ahead of the curve—delivering better solutions, improving customer satisfaction and achieving long-term profitability. The significance of innovation in business is underscored by numerous studies. According to McKinsey, 84% of executives believe innovation is critical for growth, and companies that prioritize innovation are 50% more likely to report market leadership. Furthermore, organizations that foster a culture of innovation are three times more likely to outperform competitors (https://ibn.fm/OSC6w).

Newton Golf’s new Fast Motion shaft exemplifies how a company can use innovation to sharpen its competitive edge. This latest addition to the Newton shaft lineup introduces a lighter-weight, high-performance alternative to existing models. Designed for golfers seeking increased distance and higher swing speeds, the Fast Motion shaft delivers these enhancements without compromising control or accuracy. In doing so, Newton continues to build on its strong reputation for combining advanced engineering with a deep understanding of player needs.

The Fast Motion shaft incorporates several proprietary technologies that Newton Golf has developed over time. These include the following:

  • Elongated Bend Profile, which contributes to a smooth, consistent flex throughout the swing
  • Kinetic Energy Storage, which optimizes energy transfer from the shaft to the ball
  • Symmetry 360 Construction, providing stability in all directions
  • Variable Bend Profile, which fine-tunes the release for better feel and control

With the Fast Motion shaft, Newton builds on these foundational technologies while introducing weight reduction through the use of ultralight, high-modulus Toray carbon fibers—materials known for their extraordinary strength-to-weight ratio and frequently used in aerospace and Formula 1 applications.

This product launch is timely, as the golf equipment market continues to experience growth, driven by a surge in participation and a demand for premium gear. According to the National Golf Foundation, more than 28.1 million people played golf on a course in the United States in 2024 — the highest number in over a decade (https://ibn.fm/kDzfs). The demand for quality equipment, especially in the aftermarket shaft category, has surged accordingly. Golfers of all skill levels are now investing in advanced gear that can help improve their game, and innovation is at the heart of that trend.

For Newton Golf, innovation has translated into tangible results. The company reported an 887% revenue increase in fiscal year 2024, largely driven by strong sales of its first-generation shaft lineup (https://ibn.fm/IzgnH). With the introduction of the Fast Motion shaft, Newton is poised to build on this momentum, targeting golfers who are eager to push the boundaries of performance while maintaining a high level of playability. The Fast Motion shaft was launched with widespread availability online and at fitting locations across the country, ensuring accessibility for players at all levels.

Newton’s innovative spirit is deeply rooted in its mission to “empower golfers with scientifically advanced tools that maximize consistency and accuracy, ensuring every swing is backed by the laws of physics.” The company’s product philosophy is based on rigorous testing, continuous refinement and a commitment to meeting the specific needs of today’s golfer. The Fast Motion shaft reflects these principles, demonstrating that innovation is not simply about newness but also delivering measurable improvements.

As competition in the golf equipment market intensifies, Newton Golf’s focus on innovation ensures that it won’t just keep pace—it will lead. The Fast Motion shaft is more than just a new product; it represents a larger vision for the company, one that prioritizes technological advancement, player-centric design, and a relentless pursuit of performance. In doing so, Newton Golf is carving out a position not only as a supplier of premium golf components but as an innovation leader in the industry.

For more information, visit www.NewtonGolfCo.com.

NOTE TO INVESTORS: The latest news and updates relating to NWTG are available in the company’s newsroom at https://ibn.fm/NWTG

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com

MissionIR is powered by IBN

Posted in Newton Golf Comp. NWTG | Leave a comment

SolarBank Corp. (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) Reports 395% Asset Growth in Current Fiscal Year, Focuses on Long-Term Recurring Revenue Strategy

Posted on May 27, 2025 by MissionIR
  • Total assets rose to $194 million as of March 31, 2025, as compared to the end of the last fiscal year, following a key acquisition.
  • Revenue from the company’s independent power producer segment grew from $0.3 million to $6.6 million.
  • This reflects the company’s focus on long-term income-generating assets, versus short-term engineering, procurement, and construction/project sales.
  • During the third quarter, SolarBank executed several operational milestones that align with this longer-term focus.

Disseminated on behalf of SolarBank Corporation

SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2), a premier developer and owner of renewable and clean energy projects, specializing in distributed and community solar initiatives throughout Canada and the U.S., posted fiscal third-quarter results reflecting a sharp increase in total assets with a notable shift in its revenue model.

The company reported a 395% increase in assets, rising from $39.2 million as of June 30, 2024, to $194 million by March 31, 2025. This jump was primarily driven by the acquisition of Solar Flow-Through Funds Ltd., a strategic move that significantly expanded SolarBank’s asset base and supports its evolving business model as outlined in the Q3 update (https://ibn.fm/YIsC8).

SolarBank is transitioning from a model focused on up-front Engineering, Procurement, and Construction (“EPC”) and project sales, toward building a portfolio of long-term income-generating assets through its Independent Power Producer (“IPP”) segment. While this shift may reduce short-term revenue, the long-term aim is a stable and recurring revenue stream.

Evidence of this transition can be seen in the company’s IPP revenue, which rose to $6.6 million during the nine-month period ended March 31, up from just $0.3 million in the previous year.

During the third quarter, SolarBank executed several operational milestones. The company sold its 3.26 MW Camillus Solar Project to Solar Advocate Development LLC for $7.3 million USD. Though the project sale represents immediate revenue, it also reflects SolarBank’s role in originating and maturing assets for its pipeline.

It also broke ground on its first battery energy storage system (“BESS”) project in Ontario. The construction is backed by a $25.8 million project finance facility from the Royal Bank of Canada, marking a key step in its expansion into hybrid energy storage solutions.

In the U.S., SolarBank announced a partnership with Viridi, a provider of fail-safe BESS technology, for the development of a 3.06 MW solar project with a 1.2 MWh BESS component in Buffalo, New York.

The company further disclosed a financing mandate with infrastructure investor CIM Group. The deal could unlock up to $100 million USD in project-based financing for a U.S. solar power portfolio totaling 97 MW. The CIM transaction is expected to be non-dilutive and represents a potential step-change in the scale of SolarBank’s project financing.

This shift toward long-term revenue generation through power production and storage assets is a notable strategy for investors looking beyond traditional solar EPC companies. With growing demand for clean energy and increasing interest in hybrid solutions that include storage, SolarBank is positioning itself to participate more fully in the infrastructure side of the sector.

“SolarBank continues the growth of its independent power producer portfolio. The non-dilutive CIM transaction will provide up to US$100 million in equity capital for projects that will transform SolarBank’s independent power producer asset base, creating long-term revenues for years to come,” said CEO Dr. Richard Lu. “As discussed in prior quarters, this strategy means less short-term revenue from EPC and project sales, but will have the benefit of stable long-term recurring revenues.”

For more information, visit the company’s website at SolarBankCorp.com.

This report contains forward looking information. Please refer to the press release entitled “SolarBank Announces Third Quarter Results” for additional details on the information, risks and assumptions.

NOTE TO INVESTORS: The latest news and updates relating to SUUN are available in the company’s newsroom at https://ibn.fm/SUUN

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com

MissionIR is powered by IBN

Posted in SolarBank Corp. SUUN | Leave a comment

MissionIRNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) CEO Highlights Transdermal Pain Solution on BioMedWire Podcast 

Posted on May 27, 2025 by MissionIR

Nutriband (NASDAQ: NTRB) is featured in the latest episode of The BioMedWire Podcast, part of IBN’s expanding podcast network focused on biotech and pharmaceutical innovation. In a conversation with host Carmel Fisher, Nutriband Co-Founder and CEO Gareth Sheridan outlined the company’s focus on transdermal drug delivery systems, particularly in the underserved area of pain management. Sheridan emphasized the impact of the opioid crisis on patient access to effective medications, noting that the stigma and liability concerns surrounding opioids have left many pain patients without adequate care. He introduced AVERSA(TM), Nutriband’s internally developed platform designed to deter abuse of opioid patches by making them difficult to manipulate for non-medical use.

Sheridan highlighted the dramatic contraction in the fentanyl patch market—from $4 billion in 2016 to under $1 billion today—despite the persistent size of the patient population needing these therapies. Nutriband aims to close this care gap by improving safety while maintaining accessibility. The interview offers insight into the company’s development pipeline and how AVERSA(TM) may help restore prescriber and payer confidence in transdermal opioid therapies. The podcast episode reflects IBN’s continued commitment to showcasing innovators across the life sciences industry.

To view the full press release, visit: https://ibn.fm/mZlXe

About IBN

IBN consists of financial brands introduced to the investment public over the course of 18+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (“DBP”), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
Editor@MissionIR.com

MissionIR is powered by IBN

Posted in Nutriband Inc. NTRB | Leave a comment

Soligenix Inc. (NASDAQ: SNGX) Innovative Treatment to Combat Bacterial Infection Fills Urgent Need for Alternatives to Antibiotics

Posted on May 23, 2025 by MissionIR
  • The overuse and misuse of antibiotics have led to the emergence of antibiotic-resistant bacteria, posing a significant threat to public health.
  • Soligenix’s SGX943 is a novel broad-spectrum therapy designed to treat bacterial infections without relying on conventional antibiotics.
  • Preclinical studies have demonstrated the efficacy of SGX943 in various models of bacterial infection.

In the face of escalating antibiotic resistance, the medical community is urgently seeking alternative treatments for bacterial infections. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company, is at the forefront of this effort with its development of SGX943 (dusquetide), a novel broad-spectrum therapy designed to combat bacterial infections without relying on traditional antibiotics.

Antibiotics have been a cornerstone of modern medicine, effectively treating a wide range of bacterial infections. However, their overuse and misuse have led to the emergence of antibiotic-resistant bacteria, posing a significant threat to public health. According to the Centers for Disease Control and Prevention (“CDC”), at least 2.8 million people in the United States are infected with antibiotic-resistant bacteria annually, resulting in more than 35,000 deaths (https://ibn.fm/qjibe).

The challenge is compounded by the fact that antibiotics are often specific to certain types of bacteria, and their efficacy can be compromised by resistance mechanisms. Moreover, the development of new antibiotics has not kept pace with the rapid evolution of resistant strains, leaving clinicians with limited options for treatment. Globally, the World Health Organization (“WHO”) has identified antimicrobial resistance as one of the top ten public health threats facing humanity. The situation is dire: if left unaddressed, it is projected that antibiotic resistance could cause 10 million deaths per year by 2050, surpassing cancer as a leading cause of death (https://ibn.fm/vC6MQ).

It is within this context that alternative approaches to bacterial infection treatment have become critically important. Soligenix’s SGX943 represents one such approach that could change the paradigm. SGX943 is a novel broad-spectrum therapy designed to treat bacterial infections without relying on conventional antibiotics (https://ibn.fm/5RJFl). This promising therapy takes a fundamentally different approach by leveraging the body’s innate immune system rather than directly targeting pathogens, offering a powerful new tool in the fight against resistant bacterial infections.

Soligenix’s SGX943 therapy is based on dusquetide, an Innate Defense Regulator (“IDR”) that modulates the body’s immune response rather than directly targeting bacteria. By enhancing the innate immune system, SGX943 promotes the clearance of infections and reduces inflammation, offering a broad-spectrum approach to bacterial infections.

One of the key advantages of SGX943 is its ability to be effective regardless of the bacterial species involved. This means it can be administered before the specific pathogen is identified, providing a timely intervention in acute infections. Additionally, SGX943 can be used in conjunction with existing antibiotics, potentially enhancing their efficacy and mitigating the development of resistance.

Preclinical studies have demonstrated the efficacy of SGX943 in various models of bacterial infection, including those caused by antibiotic-resistant strains. Notably, the therapy has shown promise in treating melioidosis, a serious infection caused by Burkholderia pseudomallei, which is highly resistant to many antibiotics. The U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation to SGX943 for the treatment of melioidosis, recognizing its potential to address an unmet medical need.

The rise of antibiotic-resistant bacteria underscores the critical need for innovative therapies that go beyond traditional antibiotics. Soligenix’s SGX943 offers a novel approach by harnessing the body’s innate immune system to fight infections, providing a versatile and potentially more effective treatment option. As the medical community continues to grapple with the challenges of antibiotic resistance, therapies like SGX943 represent a hopeful advancement in the fight against bacterial infections.

Headquartered in Princeton, New Jersey, Soligenix operates within the medical, biomedical and genetics sector. The company’s portfolio encompasses both specialized biotherapeutics and public health solutions, targeting areas with significant unmet medical needs. Among its leading candidates are HyBryte(TM) (SGX301), a photodynamic therapy for cutaneous T-cell lymphoma (“CTCL”), and SGX942 (dusquetide), designed to address oral mucositis in patients undergoing chemoradiation for head and neck cancer.

For more information, visit www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com

MissionIR is powered by IBN

Posted in Soligenix Inc. SNGX | Leave a comment

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary, HOPE Therapeutics, to Expand Interventional Psychiatry Treatment with Kadima Institute Acquisition

Posted on May 23, 2025 by MissionIR
  • Kadima Neuropsychiatry Institute is expected to become the clinical model for HOPE Therapeutics’ nationwide network of psychiatric clinics.
  • The acquisition brings profitability and is expected to be accretive to both revenue and EBITDA.
  • Kadima’s founder and medical director, Dr. David Feifel, a leader in interventional psychiatry, will join HOPE as Chief Medical Innovation Officer.
  • NRx’s pipeline includes investigational drugs for suicidal bipolar depression and chronic pain.
  • HOPE is targeting 30 clinic acquisitions by the end of 2025, projecting $100M in annual revenue.

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, and its wholly owned subsidiary HOPE Therapeutics, Inc., a medical and technology-driven company, are expanding their footprint in the mental health care sector with the acquisition of Kadima Neuropsychiatry Institute in La Jolla, California. The companies announced the signing of a definitive agreement to purchase the institute earlier in May 2025. Kadima is expected to serve as the clinical template for HOPE’s planned network of interventional psychiatry clinics across the U.S. (https://ibn.fm/uwHMj).

One of California’s flagship interventional psychiatry clinics, Kadima is recognized for integrating clinical care with research into emerging treatments such as psychedelic medications, and transcranial magnetic stimulation (“TMS”). The clinic offers a full range of treatments for suicidal depression, PTSD and other central nervous system (“CNS”) disorders. The institute was among the first in California to move ketamine treatments for mental health conditions out of academic research and into clinical settings.

According to the announcement, the acquisition will be accretive to revenue and EBITDA for both HOPE and NRx Pharmaceuticals. Kadima is currently profitable and expected to continue on a growth trajectory.

Dr. David Feifel, Kadima’s founder and medical director, will join HOPE as its first Chief Medical Innovation Officer after the acquisition closes. Dr. Feifel is widely regarded in the field of interventional psychiatry and has led numerous clinical trials targeting central nervous system disorders. His distinctions include serving as an elected member of the American College of Neuropharmacology, peer-elected inclusion in “Best Doctors in America,” and citation in the Castle Connolly list of “Top Doctors” — a recognition given to only 10 psychiatrists in San Diego. Dr. Feifel’s role at HOPE will be instrumental in shaping its clinical offerings and research integration.

The acquisition is still subject to customary closing conditions and financing. If completed, Kadima will become the first operational clinic under HOPE’s umbrella, setting the stage for additional acquisitions.

NRx Pharmaceuticals remains focused on the development of novel therapeutics for CNS conditions. The company’s lead compound, NRX-101, has been granted FDA Breakthrough Therapy Designation and is being developed for treatment-resistant bipolar depression with suicidality. The company is also pursuing development of NRX-100, a preservative-free IV ketamine formulation, for acute suicidality, which has received Fast Track status from the FDA.

The Kadima acquisition is part of HOPE’s broader plan to create a national network of interventional psychiatry clinics. The company aims to close on 30 such acquisitions by the end of 2025. HOPE projects $100 million in annual revenue and profitability by that time.

Commenting on the deal, Dr. Jonathan Javitt and Matthew Duffy, Co-CEOs of HOPE, said the signing of the definitive acquisition agreement marks a pivotal moment in the execution of the company’s strategy to redefine mental healthcare access and delivery of care. “Dr. David Feifel is a true pioneer in interventional psychiatry and we are honored to have him join our leadership team. With his guidance, we are accelerating the buildout of a world-class clinic network that integrates cutting-edge science with community-based care,” they said.

In addition to Kadima, HOPE has also announced agreements to acquire Dura Medical and signed a letter of intent with Neurospa TMS. These moves signal a push into outpatient psychiatric services at scale, a space seeing increased investor interest due to growing demand for mental health treatment options.

The strategy offers a dual approach to growth: a clinical-stage biotech company in NRx Pharmaceuticals, and a revenue-generating care delivery business in HOPE. The clinic network may also set the stage for a future spinout, offering NRx potential to unlock further shareholder value.

For more information, visit the company’s website at www.NRxPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to NRXP are available in the company’s newsroom at https://ibn.fm/NRXP

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com

MissionIR is powered by IBN

Posted in NRx Pharmaceuticals Inc. NRXP | Leave a comment